Angiopoietin-like protein 4: Health effects, modulating agents and structure-function relationships

Expert Review of Proteomics

Volumn 9, Issue 2, 2012, Pages 181-199

  Grootaert, Charlotte ^a   Van De Wiele, Tom ^a   Verstraete, Willy ^a   Bracke, Marc ^b   Vanhoecke, Barbara ^b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

angiopoietin like protein 4; bacteria; cancer; cleavage; hypoxia; lipid metabolism

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 4; BEZAFIBRATE; CIGLITAZONE; CIPROFIBRATE; COBALT CHLORIDE; DEFEROXAMINE; DEXAMETHASONE; FENOFIBRATE; HYDROXYICOSATETRAENOIC ACID; ISOBUTYLMETHYLXANTHINE; LINOLEIC ACID; LINOLENIC ACID; LIPOPOLYSACCHARIDE; MYRISTIC ACID; NICKEL SULFATE; OLEIC ACID; PALMITIC ACID; PIOGLITAZONE; PIRINIXIC ACID; RETINOIC ACID; ROSIGLITAZONE; STEARIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZYMOSAN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; DRUG MECHANISM; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HEALTH; HUMAN; LIPID METABOLISM; LIPOLYSIS; LUNG CANCER; LUNG PARENCHYMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANGIOPOIETINS; ANIMALS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; GASTROINTESTINAL TRACT; HUMANS; LIPID METABOLISM; LIVER; METABOLIC DISEASES; NEOPLASMS; ORGAN SPECIFICITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN ISOFORMS;

EID: 84859404214     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.12     Document Type: Review

References (106)

1. Ge H, Yang G, Huang L, Motola DL, Pourbahrami T, Li C. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J. Biol. Chem. 279(3), 2038-2045 (2004).
2. Kim I, Kim HG, Kim H et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem. J. 346, 603-610 (2000).
3. Dutton S, Trayhurn P. Regulation of angiopoietin-like protein 4/fasting-induced adipose factor (ANGPTL4/FIAF) expression in mouse white adipose tissue and 3T3-L1 adipocytes. Br. J. Nutr. 100(1), 18-26 (2008).
4. Bäckhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718-15723 (2004).
5. Brown RE, Imran A, Belsham DD, Ur E, Wilkinson M. Regulation of brain-derived resistin and FIAF in a novel hypothalamic neuronal cell line. Endocr. Abstr. 11, 280 (2006).
6. Yu X, Burgess SC, Ge H et al. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl Acad. Sci. USA, 102(5), 1767-1772 (2005).
7. Staiger H, Haas C, Machann J et al. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator activated receptor (PPAR)d and is of metabolic relevance in humans. Diabetes 58(3), 579-589 (2009).
8. Imran SA, Brown RE, Wilkinson M. Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse. Diab. Vasc. Dis. Res. 7(3), 231-238 (2010).
9. Kim HK, Youn BS, Shin MS et al. Hypothalamic ANGPTL4/Fiaf is a novel regulator of food intake and body weight. Diabetes 59(11), 2772-2780 (2010).
10. Zhu H, Li J, Qin W et al. Cloning of a novel gene, ANGPTL4 and the functional study in angiogenesis. Zhonghua Yi Xue Za Zhi 82(2), 94-99 (2002).
11. Kersten S. Regulation of lipid metabolism via angiopoietin-like proteins. Biochem. Soc. Trans. 33, 1059-1062 (2005).
12. Wiesner G, Morash BA, Ur E, Wilkinson M. Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J. Endocrinol. 180, 1-6 (2004).
13. Yoon JC, Chickering TW, Rosen ED et al. Peroxisome proliferator-activated receptor γ target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell Biol. 20, 5343-5349 (2000).
14. Belanger AJ, Lu H, Date T et al. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor γ angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1a. J. Mol. Cell Cardiol. 34(7), 765-774 (2002).
15. Kersten S, Mandard S, Tan NS et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275, 28488-28493 (2000).
16. Kersten S, Lichtenstein L, Steenbergen E et al. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 29(6), 969-974 (2009). An interesting human study from one of the major specialists in angiopoietin-like protein 4 (ANGPTL4) research, which demonstrates the role of ANGPTL4 in energy metabolism.
17. Murata M, Yudo K, Nakamura H et al. Hypoxia upregulates the expression of angiopoietin-like-4 in human articular chondrocytes: role of angiopoietin-like-4 in the expression of matrix metalloproteinases and cartilage degradation. J. Orthopaedic Res. 27(1), 50-57 (2009).
18. Josephs T, Waugh H, Kokay I, Grattan D, Thompson M. Fasting-induced adipose actor identified as a key adipokine that is up-regulated in white adipose tissue during pregnancy and lactation in the rat. J. Endocrinol. 194(2), 305-312 (2007).
19. Xu A, Lam MC, Chan KW et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc. Natl Acad. Sci. USA 102(17), 6086-6091 (2005).
20. Le Jan S, Amy C, Cazes A et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am. J. Pathol. 162(5), 1521-1528 (2003).
21. Bäckhed F, Crawford PA, O'Donnell D, Gordon JI. Postnatal lymphatic partitioning rom the blood vasculature in the small intestine requires fasting-induced adipose actor. Proc. Natl Acad. Sci. USA 104(2), 606-611 (2007).
22. Perdiguero EG, Galaup A, Durand M et al. Alteration of developmental and pathological retinal angiogenesis in angptl4-deficient mice. J. Biol. Chem. 286(42), 36841-36851 (2011).
23. Goh YY, Pal M, Chong HC et al. Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J. Biol. Chem. 285(43), 32999-33009 (2010).
24. Stapleton CM, Joo JH, Kim Y-S, Liao G, Panettieri Jr RA, Jetten AM. Induction of ANGPTL4 expression in human airway smooth muscle cells by PMA through activation of PKC and MAPK pathways. Exp. Cell Res. 316(4), 507-516 (2010).
25. Verine J, Lehmann-Che J, Soliman H et al. Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One 5(4), e10421 (2010).
26. Galaup A, Cazes A, Le Jan S et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc. Natl Acad. Sci. USA 103, 18721-18726 (2006).
27. Tian L, Zhou J, Casimiro MC et al. Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res. 69(24), 9236-9244 (2009).
28. Padua D, Zhang XH, Wang Q et al. TGFb primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133(1), 66-77 (2008).
29. He P, Borland MG, Zhu B et al. Effect of ligand activation of peroxisome proliferator-activated receptor b/d in human lung cancer cell lines. Toxicology 254(1-2), 112-117 (2008).
30. Terada LS, Nwariaku E. Escaping anoikis through ROS: ANGPTL4 controls integrin signaling through Nox1. Cancer Cell 19(3), 297-299 (2011).
31. Lichtenstein L, Berbee JF, van Dijk SJ et al. ANGPTL4 upregulates cholesterol synthesis in liver via inhibition of ECM- and HL-dependent hepatic cholesterol uptake. Arterioscler. Thromb. Vasc. Biol. 27(11), 2420-2427 (2007).
32. Zandbergen F, van Dijk S, Kersten S. Fasting-induced adipose factor/ angiopoietin-like protein 4: a potential target for dyslipidemia? Future Lipidol. 1(2), 227-236 (2006).
33. Koliwad SK, Kuo T, Shipp LE et al. Angiopoietin-like 4 (ANGPTL4/FIAF) is a direct glucocorticoid receptor target and participates in glucocorticoid- regulated triglyceride metabolism. J. Biol. Chem. 284, 25593-25601 (2009).
34. Lichtenstein L, Kersten S. Modulation of plasma TG lipolysis by angiopoietin-like proteins and GPIHBP1. Biochim. Biophys. Acta 1801(4), 415-420 (2010). Interesting review in which the effect of ANGPTL4 on lipid metabolism is discussed extensively.
35. Clement LC, Avila-Casado C, Mace C et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17(1), 117-122 (2011).
36. Fleissner CK, Huebel N, Abd El-Bary MM, Loh G, Klaus S, Blaut M. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br. J. Nutr. 104, 919-929 (2010).
37. Robciuc MR, Tahvanainen E, Jauhiainen M, Ehnholm C. Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J. Lipid Res. 51(4), 824-831 (2010).
38. Koster A, Chao YB, Mosior M et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146(11), 4943-4950 (2005).
39. Mandard S, Zandbergen F, van Straten E et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281, 934-944 (2006). Explores the different ANGPTL4 isoforms and target organs of several drugs with fasting-induced adipose factor-modulating capacities. Differences in ANGPTL4 isoforms between rodents and humans are demonstrated.
40. Lichtenstein L, Mattijssen F, de Wit NJ et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 12(6), 580-592 (2010). Interesting paper about the effect of ANGPTL4 on inflammation through extracellular matrix inhibition.
41. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104(3), 979-984 (2007).
42. Desai U, Lee EC, Chung K et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc. Natl Acad. Sci. USA 104(28), 11766-11771 (2007).
43. Adachi H, Fujiwara Y, Kondo T et al. ANGPTL4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem. Biophys. Res. Comm. 379(4), 806-811 (2009).
44. Pal M, Tan MJ, Huang RL et al. Angiopoietin-like 4 regulates epidermal differentiation. PLoS One 6(9), e25377 (2011).
45. Huang RL, Teo Z, Chong HC et al. ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood 118(14), 3990-4002 (2011). Interesting paper in which the role of ANGPTL4 in several aspects of cancer development, and especially metastasis, is extensively investigated.
46. Yoshida K, Shimizugawa T, Ono M, Furukawa H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid. Res. 43(11), 1770-1772 (2002).
47. Miida T, Hirayama S. Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events. Curr. Opin. Lipidol. 21(1), 70-75 (2010).
48. Mandard S, Zandbergen F, Tan NS et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J. Biol. Chem. 279, 34411-34420 (2004).
49. Tien ES, Davis JW, Vanden Heuvel JP. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor a coregulator. J. Biol. Chem. 279(23), 24053-24063 (2004).
50. Lal A, Peters H, St Croix B et al. Transcriptional response to hypoxia in human tumors. J. Natl Cancer Inst. 93(17), 1337-1343 (2001).
51. Liu C, Goshu E, Wells A, Fan C-M. Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. J. Biol. Chem. 278(45), 44857-44867 (2003).
52. Barz T, Hoffmann A, Panhuysen M, Spengler D. Peroxisome proliferator-activated receptor γ is a Zac target gene mediating Zac antiproliferation. Cancer Res. 66(24), 11975-11982 (2006).
53. Takeda N, Maemura K, Imai Y et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ. Res. 95(2), 146-153 (2004).
54. Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl Acad. Sci. USA 101(44), 15603-15608 (2004).
55. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARα, β, and γ in the adult rat. Endocrinology 137(1), 354-366 (1996).
56. Lemberger T, Braissant O, Juge-Aubry C et al. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann. NY Acad. Sci. 804(1), 231-251 (1996).
57. Guo L, Fang H, Collins J et al. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics 7, S18 (2006).
58. Gealekman O, Burkart A, Chouinard M, Nicoloro SM, Straubhaar J, Corvera S. Enhanced angiogenesis in obesity and in response to PPARγ activators through adipocyte VEGF and ANGPTL4 production. Am. J. Physiol. Endocrinol. Metab. 295(5), 1056-1064 (2008).
59. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13(2), 167-171 (2001).
60. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 100(2), 227-235 (2008).
61. Cazes A, Galaup A, Chomel C et al. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ. Res. 99(11), 1207-1215 (2006). Demonstrates the different effects of native and cleaved ANGPTL4 isoforms on angiogenesis.
62. Brant KA, Fabisiak JP. Nickel and the microbial toxin, MALP-2, stimulate proangiogenic mediators from human lung fibroblasts via a HIF-1a and COX-2-mediated pathway. Toxicol. Sci. 107(1), 227-237 (2009).
63. 2 ratio and confers anoikis resistance to tumors. Cancer Cell 19(3), 401-415 (2011).
64. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92(3), 347-355 (2004).
65. Ifon ET, Pang AL, Johnson W et al. U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int. 5, 19-32 (2005).
66. Dempsey EC, Cool CD, Littler CM. Lung disease and PKCs. Pharmacol. Res. 55(6), 545-559 (2007).
67. Barnett ME, Madgwick DK, Takemoto DJ. Protein kinase C as a stress sensor. Cell Signal. 19(9), 1820-1829 (2007).
68. Brown R, Imran SA, Belsham DD, Ur E, Wilkinson M. Adipokine gene expression in a novel hypothalamic neuronal cell line: resistin-dependent regulation of fasting-induced adipose factor and SOCS-3. Neuroendocrinology 85(4), 232-241 (2007).
69. 2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ. Microbiol. 13(7), 1778-1789 (2011).
70. Are A, Aronsson L, Wang S et al. Enterococcus faecalis from newborn babies regulate endogenous PPARg activity and IL-10 levels in colonic epithelial cells. Proc. Natl Acad. Sci. USA 105(6), 1943-1948 (2008).
71. Aronsson L, Huang Y, Parini P et al. Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One 5(9), e13078 (2010). Demonstrates for the first time that addition of probiotics increases plasma ANGPTL4 levels and decreases fat storage.
72. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7), 1761-1772 (2007).
73. Huang Q-H, Hruby VJ, Tatro JB. Role of central melanocortins in endotoxin-induced anorexia. Am. J. Physiol. Regul. Integ. Comp. Physiol. 276(3), 864-871 (1999).
74. Rummel C, Inoue W, Sachot C, Poole S, Hubschle T, Luheshi GN. Selective contribution of interleukin-6 and leptin to brain inflammatory signals induced by systemic LPS injection in mice. J. Comp. Neurol. 511(3), 373-395 (2008).
75. Brown R, Imran SA, Wilkinson M. Lipopolysaccharide (LPS) stimulates adipokine and socs3 gene expression in mouse brain and pituitary gland in vivo, and in N-1 hypothalamic neurons in vitro. J. Neuroimmunol. 209(1-2), 96-103 (2009).
76. Lu B, Moser A, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem. Biophys. Res. Commun. 391(4), 1737-1741 (2010).
77. Autiero M, Waltenberger J, Communi D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9(7), 936-943 (2003).
78. Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. J. Pharm. 140, 595-610 (2003).
79. Wilson CA, Cajulis EE, Green JL et al. HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 7(6), 1058-1079 (2005).
80. Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Muller-Brusselbach S, Muller R. Transcriptional profiling identifies functional interactions of TGFβ and PPARβ/δ signaling: synergistic induction of ANGPTL4 transcription. J. Biol. Chem. 285(38), 29469-29479 (2010).
81. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl Acad. Sci. USA 103(46), 17450-17455 (2006).
82. Yang Y-H, Wang Y, Lam KSL et al. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler. Thromb. Vasc. Biol. 28(5), 835-840 (2008).
83. Yau MH, Wang Y, Lam KS, Zhang J, Wu D, Xu A. A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J. Biol. Chem. 284(18), 11942-11952 (2009).
84. Li C. Not all angiopoietin-like proteins (Angptls) are created equal: insights from molecular, genetic, and pharmacological studies on the mechanism of ECM inhibition by Angptl3 and Angptl4. Curr. Opin. Lipidol. 20(4), 357-359 (2009).
85. Ge H, Yang G, Yu X, Pourbahrami T, Li C. Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4. J. Lipid Res. 45(11), 2071-2079 (2004).
86. Yin W, Romeo S, Chang S, Grishin NV, Hobbs HH, Cohen JC. Genetic variation in ANGPTL4 provides insights into protein processing and function. J. Biol. Chem. 284(19), 13213-13222 (2009).
87. Chomel C, Cazes A, Faye C et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J. 23(3), 940-949 (2009).
88. Lei X, Shi F, Basu D et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J. Biol. Chem. 286(18), 15747-15756 (2011). Interesting paper that highlights the newest findings about ANGPTL4 isoforms.
89. Georgiadi A, Lichtenstein L, Degenhardt T et al. Induction of cardiac ANGPTL4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor b/d and protects against fatty acid-induced oxidative stress. Circ. Res. 106(11), 1712-1721 (2010).
90. Mandard S, Müller M, Kersten S. Peroxisome proliferator-activated receptor a target genes. Cell Mol. Life Sci. 61(4), 393-416 (2004).
91. Goh YY, Pal M, Chong HC et al. Angiopoietin-like 4 interacts with integrins β1 and β5 to modulate keratinocyte migration. Am. J. Pathol. 177(6), 2791-2803 (2010).
92. Shan L, Yu XC, Liu Z et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J. Biol. Chem. 284(3), 1419-1424 (2009).
93. Lee EC, Desai U, Gololobov G et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (ECM). J. Biol. Chem. 284(20), 13735-13745 (2009).
94. Zandbergen F, Mandard S, Escher P et al. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem. J. 392(2), 313-324 (2005).
95. Romeo S, Pennacchio LA, Fu Y et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39(4), 513-516 (2007).
96. Talmud PJ, Smart M, Presswood E et al. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler. Thromb. Vasc. Biol. 28(12), 2319-2325 (2008).
97. Smart-Halajko M, Kelley-Hedgepeth A, Montefusco M et al. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in non-Hispanic white Americans from the Look AHEAD clinical trial. BMC Med. Genet. 12(1), 89-96 (2011).
98. Naruhn S, Meissner W, Adhikary T et al. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist. Mol. Pharmacol. 77(2), 171-184 (2010).
99. Szatmari I, Töröcsik D, Agostini M et al. PPARγ regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110(9), 3271-3280 (2007).
100. Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor β/δ and retinoic acid receptor. Mol. Cell Biol. 29(12), 3286-3296 (2009).
101. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 455(3), 479-492 (2007).
102. Viemann D, Schmidt M, Tenbrock K et al. The contact allergen nickel triggers a unique inflammatory and proangiogenic gene expression pattern via activation of NF-κB and hypoxia-inducible factor 1α. J. Immunol. 178(5), 3198-3207 (2007).
103. Lee DC, Romero R, Kim CJ et al. Surfactant protein-A as an anti-inflammatory component in the amnion: implications for human pregnancy. J. Immunol. 184(11), 6479-6491 (2010).
104. Flores-Morales A, Stahlberg N, Tollet-Egnell P et al. Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology 142(7), 3163-3176 (2001).
105. Yamada T, Ozaki N, Kato Y, Miura Y, Oiso Y. Insulin downregulates angiopoietin-like protein 4 mRNA in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 347(4), 1138-1144 (2006).
106. McLaughlin JN, Mazzoni MR, Cleator JH et al. Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells. J. Biol. Chem. 280(23), 22172-22180 (2005).